Oruka Therapeutics (ORKA) Capital Expenditures (2010 - 2026)
Oruka Therapeutics' (ORKA) quarterly Capital Expenditures came in at $73000.0 in Q1 2026, up 461.54% year-on-year from $13000.0 in Q1 2025, and up 15.87% quarter-over-quarter from $63000.0 in Q4 2025.
Oruka Therapeutics (ORKA) Capital Expenditures (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Capital Expenditures history runs 14 years deep, the most recent figure standing at $73000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 461.54% year-over-year to $73000.0 in Q1 2026; TTM through Mar 2026 was $269000.0, a 2345.45% increase from a year earlier, with the FY2025 full-year figure at $209000.0, up 386.05% from the prior year.
- Capital Expenditures rose to $73000.0 in Q1 2026 per ORKA's latest filing, from $63000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $99000.0 in Q3 2025 and bottomed at -$2000.0 in Q4 2022.
- The 3-year median for Capital Expenditures is $34000.0 (2025), against an average of $40285.7.
- Across the five-year window, Capital Expenditures slumped 66.67% in 2022 and jumped 461.54% in 2026, its largest moves.
- Year by year, Capital Expenditures stood at -$2000.0 in 2022, then jumped by 3250.0% to $63000.0 in 2025, then rose by 15.87% to $73000.0 in 2026.
- Per Business Quant, the three latest ORKA Capital Expenditures figures stand at $73000.0 (Q1 2026), $63000.0 (Q4 2025), and $99000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Oruka Therapeutics | 36.09 Mn | -795.06 Mn | - | 73,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73,000.00 |
| Mar 31, 2026 | 73,000.00 |
| Dec 31, 2025 | 63,000.00 |
| Dec 31, 2025 | 63,000.00 |
| Sep 30, 2025 | 99,000.00 |
| Sep 30, 2025 | 99,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Dec 31, 2022 | -2,000.00 |
| Dec 31, 2022 | -2,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Sep 30, 2021 | -2,000.00 |
| Sep 30, 2021 | -2,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Mar 31, 2021 | 6,000.00 |
| Mar 31, 2021 | 6,000.00 |